Protein therapeutics: a summary and pharmacological classification (Q34728463)

4 August 2017

1 reference

title

Protein therapeutics: a summary and pharmacological classification (English)

1 reference

4 August 2017

1 reference

Benjamin Leader

1

1 reference

4 August 2017

Quentin J Baca

series ordinal

2

1 reference

4 August 2017

David E Golan

series ordinal

3

1 reference

4 August 2017

publication date

1 January 2008

1 reference

Nature Reviews Drug Discovery

4 August 2017

published in

1 reference

4 August 2017

volume

7

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

21-39

1 reference

Bioinformatics. Gene counters struggle to get the right answer

4 August 2017

cites work

1 reference

Initial sequencing and analysis of the human genome

31 March 2020

1 reference

The Sequence of the Human Genome

31 March 2020

1 reference

Trends in development and approval times for new therapeutics in the United States

31 March 2020

1 reference

Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. American Thoracic Society

31 March 2020

1 reference

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

31 March 2020

1 reference

Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine.

31 March 2020

1 reference

Large-scale transient expression in mammalian cells for recombinant protein production

31 March 2020

1 reference

New molecular biology methods for protein engineering

31 March 2020

1 reference

Protein engineering 20 years on.

31 March 2020

1 reference

Development and characterization of novel erythropoiesis stimulating protein (NESP)

31 March 2020

1 reference

Expression in Escherichia coli of chemically synthesized genes for human insulin

31 March 2020

1 reference

Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients.

31 March 2020

1 reference

Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men

31 March 2020

1 reference

Gaucher's disease: a review

31 March 2020

1 reference

Alglucerase. A review of its therapeutic use in Gaucher's disease

31 March 2020

1 reference

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

31 March 2020

1 reference

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

31 March 2020

1 reference

Treatment of Hemophilia with Glycine-Precipitated Factor VIII

31 March 2020

1 reference

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

31 March 2020

1 reference

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

31 March 2020

1 reference

A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).

31 March 2020

1 reference

Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.

31 March 2020

1 reference

National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group

31 March 2020

1 reference

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).

31 March 2020

1 reference

Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins

31 March 2020

1 reference

Use of recombinant human chorionic gonadotropin in ovulation induction

31 March 2020

1 reference

A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction

31 March 2020

1 reference

Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

31 March 2020

1 reference

Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion

31 March 2020

1 reference

Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study

31 March 2020

1 reference

Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience

31 March 2020

1 reference

A comparison of reteplase with alteplase for acute myocardial infarction

31 March 2020

1 reference

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

31 March 2020

1 reference

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

31 March 2020

1 reference

Dosing with recombinant factor viia based on current evidence

31 March 2020

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

31 March 2020

1 reference

Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis

31 March 2020

1 reference

A clinical evaluation of enzymatic debridement with papain-urea-chlorophyllin ointment

31 March 2020

1 reference

Collagenase in the Treatment of Dermal and Decubitus Ulcers

31 March 2020

1 reference

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

31 March 2020

1 reference

Pegaspargase: an alternative?

31 March 2020

1 reference

Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia

31 March 2020

1 reference

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

31 March 2020

1 reference

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

31 March 2020

1 reference

Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature

31 March 2020

1 reference

Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial Infarction

31 March 2020

1 reference

A Randomized Trial of Intracoronary Streptokinase in the Treatment of Acute Myocardial Infarction

31 March 2020

1 reference

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

31 March 2020

1 reference

Antibody humanization: a case of the 'Emperor's new clothes'?

31 March 2020

1 reference

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

31 March 2020

1 reference

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

31 March 2020

1 reference

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

31 March 2020

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

31 March 2020

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

31 March 2020

1 reference

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

31 March 2020

1 reference

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

31 March 2020

1 reference

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

31 March 2020

1 reference

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

31 March 2020

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

31 March 2020

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

31 March 2020

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

31 March 2020

1 reference

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

31 March 2020

1 reference

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

31 March 2020

1 reference

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

31 March 2020

1 reference

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

31 March 2020

1 reference

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

31 March 2020

1 reference

Intercellular delivery of functional p53 by the herpesvirus protein VP22.

31 March 2020

1 reference

CuZn superoxide dismutase (SOD-1):tetanus toxin fragment C hybrid protein for targeted delivery of SOD-1 to neuronal cells

31 March 2020

1 reference

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

31 March 2020

1 reference

Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff

31 March 2020

1 reference

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium

31 March 2020

1 reference

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group

31 March 2020

1 reference

GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side

31 March 2020

1 reference

Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin

31 March 2020

1 reference

Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants

31 March 2020

1 reference

Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test

31 March 2020

1 reference

Cloning of a Mycobacterium tuberculosis gene encoding a purifed protein derivative protein that elicits strong tuberculosis-specific delayed-type hypersensitivity

31 March 2020

1 reference

Comparison of sensitivities to two commercially available tuberculin skin test reagents in persons with recent tuberculosis

31 March 2020

1 reference

Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency

31 March 2020

1 reference

New approach to the diagnosis of growth hormone deficiency in adults

31 March 2020

1 reference

Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma

31 March 2020

1 reference

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

31 March 2020

1 reference

Increased sensitivity of HIV-1 antibody detection

31 March 2020

1 reference

Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda

31 March 2020

1 reference

Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells.

31 March 2020

1 reference

Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay

31 March 2020

1 reference

Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays

31 March 2020

1 reference

Improving protein therapeutics with sustained-release formulations

31 March 2020

1 reference

Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins

31 March 2020

1 reference

Bioequivalence and the immunogenicity of biopharmaceuticals

31 March 2020

1 reference

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

31 March 2020

1 reference

Development trends for monoclonal antibody cancer therapeutics.

31 March 2020

1 reference

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

31 March 2020

1 reference

Thrombocytopenia caused by the development of antibodies to thrombopoietin

31 March 2020

1 reference

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor

31 March 2020

1 reference

Protein drug stability: a formulation challenge

31 March 2020

1 reference

Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin

31 March 2020

1 reference

Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature?

31 March 2020

1 reference

Process economics of animal cell and bacterial fermentations: a case study analysis of tissue plasminogen activator

31 March 2020

1 reference

Transgenic chickens as bioreactors for protein-based drugs

31 March 2020

1 reference

Making an ally from an enemy: plant virology and the new agriculture

31 March 2020

1 reference

Fluid mixing in shaken bioreactors: Implications for scale-up predictions from microlitre-scale microbial and mammalian cell cultures

31 March 2020

1 reference

Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis

31 March 2020

1 reference

Growth hormone treatment in growth-retarded adolescents after renal transplant

31 March 2020

1 reference

The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency

31 March 2020

1 reference

31 March 2020

1 reference

31 March 2020

1 reference

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

Factor IX inhibitors and anaphylaxis in hemophilia B.

31 March 2020

1 reference

Actions and Interactions of Antithrombin and Heparin

31 March 2020

1 reference

Treatment of congenital antithrombin III deficiency with concentrates

31 March 2020

1 reference

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial

31 March 2020

1 reference

Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial

31 March 2020

1 reference

Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study

31 March 2020

1 reference

Large porous particles for pulmonary drug delivery

31 March 2020

1 reference

31 March 2020

1 reference

Efficacy and safety of insulin glulisine in patients with type 1 diabetes

31 March 2020

1 reference

Insulin detemir: a new basal insulin analogue

31 March 2020

1 reference

Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial

31 March 2020

1 reference

Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro

31 March 2020

1 reference

Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial

31 March 2020

1 reference

Human alpha-L-iduronidase: cDNA isolation and expression

31 March 2020

1 reference

The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase

31 March 2020

1 reference

Enzyme-replacement therapy in mucopolysaccharidosis I.

31 March 2020

1 reference

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

31 March 2020

1 reference

31 March 2020

1 reference

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

31 March 2020

1 reference

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

31 March 2020

1 reference

Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase

31 March 2020

1 reference

Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases

31 March 2020

1 reference

A comparison of albumin and saline for fluid resuscitation in the intensive care unit

31 March 2020

1 reference

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

31 March 2020

1 reference

The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study

31 March 2020

1 reference

Interferons in human papillomavirus infections

31 March 2020

1 reference

Therapy of hepatitis C: overview

31 March 2020

1 reference

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

31 March 2020

1 reference

A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection

31 March 2020

1 reference

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

31 March 2020

1 reference

Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: a functional study

31 March 2020

1 reference

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma

31 March 2020

1 reference

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

31 March 2020

1 reference

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

31 March 2020

1 reference

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

31 March 2020

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

31 March 2020

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

31 March 2020

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

31 March 2020

1 reference

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

31 March 2020

1 reference

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

31 March 2020

1 reference

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte

31 March 2020

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

31 March 2020

1 reference

Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial

31 March 2020

1 reference

Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived)

31 March 2020

1 reference

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

31 March 2020

1 reference

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

31 March 2020

1 reference

Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.

31 March 2020

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

31 March 2020

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

31 March 2020

1 reference

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

31 March 2020

1 reference

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis

31 March 2020

1 reference

Long-term treatment of osteopetrosis with recombinant human interferon gamma

31 March 2020

1 reference

Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma

31 March 2020

1 reference

The interferons. Mechanisms of action and clinical applications

31 March 2020

1 reference

Recombinant human interferon gamma therapy for osteopetrosis

31 March 2020

1 reference

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

31 March 2020

1 reference

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

31 March 2020

1 reference

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

31 March 2020

1 reference

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism

31 March 2020

1 reference

Urokinase in Pulmonary Embolism

31 March 2020

1 reference

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

31 March 2020

1 reference

A brief history of calcitonin.

31 March 2020

1 reference

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

31 March 2020

1 reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

31 March 2020

1 reference

Recombinant human parathyroid hormone

31 March 2020

1 reference

Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis

31 March 2020

1 reference

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

31 March 2020

1 reference

Treatment of type II gastric carcinoid tumors with somatostatin analogues

31 March 2020

1 reference

31 March 2020

1 reference

The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report

31 March 2020

1 reference

Complications of thermal capsulorrhaphy of the shoulder.

31 March 2020

1 reference

Palifermin for oral mucositis after intensive therapy for hematologic cancers

31 March 2020

1 reference

Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies

31 March 2020

1 reference

Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.

31 March 2020

1 reference

Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group

31 March 2020

1 reference

Cleansing properties of stabilized trypsin and streptokinase-streptodornase in necrotic leg ulcers

31 March 2020

1 reference

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial

31 March 2020

1 reference

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

31 March 2020

1 reference

Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25

31 March 2020

1 reference

Therapeutic uses of botulinum toxin

31 March 2020

1 reference

Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin

31 March 2020

1 reference

A comparison of topical and retrobulbar anesthesia for cataract surgery.

31 March 2020

1 reference

Effect of hyaluronidase on ocular motility and eyelid function in sub-Tenon's anaesthesia: randomised controlled trial

31 March 2020

1 reference

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

31 March 2020

1 reference

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

31 March 2020

1 reference

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

31 March 2020

1 reference

Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

31 March 2020

1 reference

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

31 March 2020

1 reference

A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.

31 March 2020

1 reference

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

31 March 2020

1 reference

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

31 March 2020

1 reference

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

31 March 2020

1 reference

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

31 March 2020

1 reference

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

31 March 2020

1 reference

New drugs for rheumatoid arthritis

31 March 2020

1 reference

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

31 March 2020

1 reference

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

31 March 2020

1 reference

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

31 March 2020

1 reference

A controlled trial of natalizumab for relapsing multiple sclerosis

31 March 2020

1 reference

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

31 March 2020

1 reference

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

31 March 2020

1 reference

Immunosuppressive strategies in transplantation

31 March 2020

1 reference

Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group

31 March 2020

1 reference

Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts

31 March 2020

1 reference

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

31 March 2020

1 reference

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

31 March 2020

1 reference

A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation

31 March 2020

1 reference

A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection

31 March 2020

1 reference

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

31 March 2020

1 reference

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

31 March 2020

1 reference

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

31 March 2020

1 reference

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

31 March 2020

1 reference

Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation

31 March 2020

1 reference

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

31 March 2020

1 reference

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

31 March 2020

1 reference

Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation.

31 March 2020

1 reference

Efficacy, safety, and use of snake antivenoms in the United States.

31 March 2020

1 reference

Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies

31 March 2020

1 reference

Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study

31 March 2020

1 reference

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

31 March 2020

1 reference

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

31 March 2020

1 reference

Hypoglycaemia in childhood diabetes. II. Effect of subcutaneous or intramuscular injection of different doses of glucagon

31 March 2020

1 reference

Clinical studies with glucagon in children

31 March 2020

1 reference

A double-blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin

31 March 2020

1 reference

Comparison of Biologic Porcine Secretin, Synthetic Porcine Secretin, and Synthetic Human Secretin in Pancreatic Function Testing

31 March 2020

1 reference

Neuroendocrine gastrointestinal tumours

31 March 2020

1 reference

Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates

31 March 2020

1 reference

Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer

31 March 2020

1 reference

Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma

31 March 2020

1 reference

Detection and Staging of Small Cell Lung Carcinoma with a Technetium-labeled Monoclonal Antibody A Comparison with Standard Staging Methods

31 March 2020

1 reference

Antimyosin imaging in acute transmural myocardial infarctions: results of a multicenter clinical trial

31 March 2020

1 reference

A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis

31 March 2020

1 reference

The use of hematopoietic growth factors in treating HIV infection

31 March 2020

1 reference

7 January 2021

Ethics, policy, and rare genetic disorders: the case of Gaucher disease in Israel

1 reference

7 January 2021

Treatment of acute renal allograft rejection with OKT3 monoclonal antibody

1 reference

7 January 2021

1 reference

7 January 2021

Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD003973

Identifiers

DOI

10.1038/NRD2399

1 reference

4 August 2017

1 reference